We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
[Medical and surgical treatment of Parkinson's disease].
La Presse Médicale 2017 March
The treatment of Parkinson's disease is symptomatic with the use of dopaminergic medications: levodopa, dopaminergic agonists and enzymatic inhibitors. At the initial stage, the main goals are to improve the quality of life of patients and delay the onset of motor complications, using a combination of these therapies taking into account both clinical disability and tolerance of different treatments. At the stage of motor and non-motor fluctuations inhibitors of MAO-B and COMT are proposed; amantadine may limit moderate dyskinesias. At the stage of disabling fluctuations continuous dopaminergic strategy is discussed: deep brain stimulation of different targets, subcutaneous apomorphine pump and intra intestinal Duodopa(®) administration. The monitoring of side effects remains essential for an early adjustment of medications; mainly nausea, orthostatic hypotension, drowsiness and sleep attacks, dyskinesias and behavioral disorders (hallucinations, impulse control disorders). A care pathway published in 2014 by the HAS develops the management process of parkinsonism and its multidisciplinary outpatient.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app